CI-SBPH@EC2610A

China Bio-Pharmaceutical Completes Phase III Clinical Enrollment for Two Drugs

China Bio-Pharmaceutical Completes Phase III Clinical Trial Enrollment For TQB2102 In HER2 Low-Expression Breast Cancer

China Biopharmaceutical Completes Patient Recruitment for LM-302's Phase III Clinical Trial

Bocom International Maintains Buy Rating on China Bio

CMBI Adjusts China Bio-Pharmaceutical's Net Profit Forecast and Maintains Buy Rating

China BioPharm Ltd. Announces Positive Phase II Clinical Trial Results for TQA3605 in Chronic Hepatitis B Treatment

China Biopharmaceutical Acquires Herjia for 120 Million

China Biopharmaceutical Announces Acquisition of Hygieia Biotech

China Biology Pharmaceutical Announces Willingness to Acquire More Biotech Companies in China and Seek Cross-border Cooperation

China Bio-Pharmaceutical acquires 100% equity of Herjia

CSOBP Management Outlines Business Prospects and Expresses Optimism on National Medical Insurance Negotiations

China Biopharmaceuticals receives executive 增持

China Biopharma Initiates Phase III Clinical Trial of TDI01 for Idiopathic Pulmonary Fibrosis

China Biologic Completes Phase II Clinical Trials for Psoriasis Drug TQH3906

Xie Xin Increased Holdings in China Bio-Pharmaceuticals

Nomura Downgrades China Biologic Products Target Price to HKD 8.3

Chinese Innovative Pharmaceutical Companies Discuss Overseas Strategies: From 'Riding Others' Ships' to 'Building Their Own Ships'

Zentelxin (Cumbexil) Approved for Market by Chong Kun Dang Pharmaceutical

ChinaBiot's Innovative Drug TQF3250 Capsules Clinical Trial Application Approved by Chinese and US Authorities

China Biopharmaceutical's Rotigotine Patch Approved for Market Launch by NMPA

BOER POWER

KNOWLEDGE ATLAS

WAI CHUN GROUP

TOUYUN BIOTECH

TJCD

ASIA ENERGY LOG

HING LEE (HK)

TBKS HLDGS

HUAYUEXPRESSWAY

01177

516500

159837

159849

512290

159859

The Bank of America Securities research report indicates that two drugs from SINO BIOPHARM, TQB2102 and LM302, have recently completed the enrollment of subjects for Phase III clinical studies. Among them, LM302 is the world's first CLDN18.2 antibody-drug conjugate to complete subject enrollment for Phase III registration clinical studies, which is expected to provide new treatment options for patients. The firm currently sets a target price of 8.6 yuan and reaffirms a "Buy" rating

AASTOCKS

SINO BIOPHARM

Founder Fubon CSI Medicine and Medical Device Innovation ETF

China Universal 800 Health Care ETF

Guotai SSE STAR Brand Name Drug ETF

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

Penghua SSE STAR Biology and Medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Tianhong CNI BIOMEDICINE ETF

ICBCCS SSE STAR Biology and Medicine ETF

"Big Banks" Bank of America Securities: The progress of two drugs from SINO BIOPHARM is positive, reiterating a "Buy" rating

513120

513700

159102

Sino Biopharmaceutical shares rose 5.6% to HK$6.97, marking the largest one-day gain since November 13. The stock reached its highest point since January 29, continuing a six-day upward trend. The company announced that its breast cancer drug TQB2102, a HER2 bispecific ADC, is in phase III clinical trials, with subject enrollment recently completed. Year-to-date, the stock is up 12%, while the Hang Seng Biotech Index has increased by 13.4%.

Reuters

E Fund CSI 300 Health Care ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Penghua CSI HK Connect Health Care Composite ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Huaan Hang Seng Biotech ETF

Guotai Hang Seng Biotech ETF

ChinaAMC SSE Health Care ETF Initiating Fund

China Southern Hang Seng Biotech ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Universal CSI Biotechnology Theme Index Initiating Fund(LOF)-A

Sino Biopharmaceutical rises on progress of breast cancer drug

01093

01801

02269

08189

08037

02509

The Hang Seng Biotechnology Index rose over 4% intraday, CSPC PHARMA rose over 7%, INNOVENT BIO rose nearly 7%, WUXI BIO and SINO BIOPHARM rose over 5%

Wallstreetcn

CSPC PHARMA

INNOVENT BIO

WUXI BIO

TEDA BIOMEDICAL

CH BIOTECH SER

QYUNS-B

Sino Biopharmaceutical Completes Subject Enrollment in Phase 3 Trial of Breast Cancer Drug

marketscreener

Sino Biopharmaceutical Completes Subject Enrollment in Phase 3 Trial of Breast Cancer Drug

Sino Biopharmaceutical Limited has completed enrollment for a Phase III clinical trial of TQB2102, a HER2 bispecific antibody-drug conjugate, targeting HER2-low recurrent or metastatic breast cancer. The trial, named TQB2102-III-01, will compare the efficacy and safety of TQB2102 against standard chemotherapy. Results are pending. This announcement was published via the Hong Kong Stock Exchange.

Bosera Hang Seng SCHK Innovative Drug Select ETF

Bosera Hang Seng Health Care ETF(QDII)

Sino Biopharm Completes Enrollment for Phase III Trial of HER2 Bispecific ADC in HER2-Low Breast Cancer

Sino Biopharm's LM-302 Completes Phase 3 Trial Enrollment in Gastric Cancer Study

Sino Biopharm's LM-302 Completes Phase 3 Trial Enrollment in Gastric Cancer Study

Sino Biopharmaceutical’s subsidiary, LaNova Medicines, has completed Phase III enrollment for tecotabart vedotin (LM-302), the first CLDN18.2 ADC to reach this milestone. This trial targets advanced gastric and gastroesophageal junction adenocarcinoma. Early data shows promising response rates, and a Phase III first-line trial is planned in China. The company aims to enhance its oncology portfolio and global competitiveness, with regulatory support in China and the U.S. The current analyst rating for Sino Biopharmaceutical (HK:1177) is a Hold with a price target of HK$7.50.

Tip Ranks

Sino Biopharm’s CLDN18.2 ADC Becomes First to Complete Phase III Enrollment

Sino Biopharmaceutical Limited has announced the successful completion of patient enrollment for the Phase III registration study of Tecotabart Vedotin (LM-302), an antibody-drug conjugate targeting CLDN18.2. The study focuses on patients with CLDN18.2-positive, locally advanced or metastatic gastric and gastroesophageal junction carcinoma in third-line and later therapy. LM-302 is the first CLDN18.2-ADC to complete patient enrollment in a pivotal Phase III study. Early phase study results combining LM-302 with Toripalimab were presented at the ASCO Annual Meeting 2025.

JUNSHI BIO

Junshi Biosciences

Sino Biopharmaceutical meldet Abschluss der Patienteneinschreibung für Phase-III-Studie von Tecotabart Vedotin bei Magenkrebs

01530

SINO BIOPHARM (1177.HK) has recently experienced a prolonged period of low price fluctuations, with daily candlesticks showing slight alternation between bullish and bearish trends, and an overall downward shift in focus. In the past few trading days, the stock price has retraced to the vicinity of previous low ranges, with trading volume continuously shrinking and market participants showing strong wait-and-see sentiment. From a technical perspective, the MACD indicator remains in a death cross, with significant green bars, indicating a large divergence between bulls and bears in the short term. 

Fundamentally, the company focuses on its pharmaceutical core business, possessing strong R&D capabilities and product resources. However, it is affected by industry medical insurance cost control, centralized procurement pressures, and a slowdown in sequential performance growth, leading to weakened market confidence. The overall valuation of the Hong Kong pharmaceutical sector is under pressure, with limited inflow momentum from northbound and foreign capital, and a noticeable decline in trading enthusiasm. Meanwhile, the global interest rate hike cycle and the continued weakness of the Hong Kong dollar are also macroeconomic headwinds that have further suppressed risk appetite for capital.

Technically, current support is located in the HKD 3.5-3.8 range, which has historically seen rebounds after multiple touches. However, the sustainability of recent rebounds has been average. If there is a short-term increase in volume and the price stabilizes above HKD 4, it may open a window for a rebound and repair the weak pattern. Conversely, if the price breaks support on low volume, there may be a risk of inertia downward movement. Investors are advised to closely monitor the distribution of main funds and the short-term sector atmosphere, and to avoid blindly entering large positions until technical signals are clear. If a rebound stabilizes alongside unusual movements in incremental funds, light participation in short-term opportunities may be considered, with an overall focus on stability and risk control as a priority

Technical Forecast

3SBIO

Morning Trend | SINO BIOPHARM rebounds from low points, will a rebound window open?

Hong Kong stocks continued their upward trend on July 28, with the cryptocurrency, innovative drug, gaming, and insurance sectors performing well. Hong Kong's &#34;Stablecoin Ordinance&#34; will officially take effect on August 1, marking the countdown to stablecoin issuance; the innovative drug sector was boosted by Hengrui Pharmaceuticals securing a $12 billion order; insurance stocks extended their gains as industry anti-internal competition and interest rate cuts improved profit prospects; gaming stocks benefited from Macau's July gaming revenue exceeding expectations and Thailand's withdrawal of the casino bill.

HENGRUI PHARMA

Hengrui Pharma

OSL GROUP

CPIC

SUNSHINE INS

SANDS CHINA LTD

Sands China

WYNN MACAU

CR HOLDINGS

CHINA LIFE

China Life

MELCO INT'L DEV

GUOTAI JUNAN I

AIA-R

AIA Group

SJM HOLDINGS

Hot Trades in Hong Kong Stocks (7.28)｜Cryptocurrency, Innovative Drugs, Insurance, and Gaming Sectors Shine, Hengrui Pharmaceuticals Soars 15% at Midday

CI-SBPH@EC2610A(19019.HK)

"Big Banks" Bank of America Securities: The progress of two drugs from SINO BIOPHARM is positive, reiterating a "Buy" rating

Sino Biopharmaceutical rises on progress of breast cancer drug

The Hang Seng Biotechnology Index rose over 4% intraday, CSPC PHARMA rose over 7%, INNOVENT BIO rose nearly 7%, WUXI BIO and SINO BIOPHARM rose over 5%

Sino Biopharmaceutical Completes Subject Enrollment in Phase 3 Trial of Breast Cancer Drug

Sino Biopharm Completes Enrollment for Phase III Trial of HER2 Bispecific ADC in HER2-Low Breast Cancer